Previous 10 | Next 10 |
CHARLESTON, S.C., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce that the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) have recently published the new ‘Guidelines for ...
CHARLESTON, S.C., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce changes to its director composition planned for the first quarter of 2020. Mr. Gilles Gagnon (M.Sc., MBA, ICD.D) will join the board of directors of the Company o...
Aeterna Zentaris (NASDAQ: AEZS ): Q3 GAAP EPS of -$0.02 beats by $0.15 . Revenue of $0.28M (+64.7% Y/Y) beats by $0.04M . Press Release More news on: Aeterna Zentaris Inc., Earnings news and commentary, Healthcare stocks news, ,
CHARLESTON, S.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the third quarter ended September 30, 2019. All Amounts are in U.S. Dollars Highlights Net loss for the third qua...
CHARLESTON, S.C., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced the appointment of Klaus Paulini as President and Chief Executive Officer of the Company, effective today, replacing Michael Ward. Dr. Paulini will also serve as a Director...
CHARLESTON, S.C., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), a specialty biopharmaceutical company engaged in commercializing novel pharmaceutical therapies, principally through out-licensing arrangements, announced the closing of its previou...
Aeterna Zentaris (AEZS) reported an awkward earnings report that exposed the fact that the company only pulled in ~0.2M in revenue, which was actually a slight miss. However, the company beat on EPS coming in at $0.01 vs. the expected -$0.14 EPS. The Q2 earnings were similar to the Q1 earnings...
CHARLESTON, S.C., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today announced that Jonathan Pollack has resigned as a director of the Company for personal reasons, effective immediately. The board of directors of the Company has appointed Carolyn Egb...
Aeterna Zentaris (NASDAQ: AEZS ): GAAP EPS of $0.01 beats by $0.15 . More news on: Aeterna Zentaris Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CHARLESTON, S.C., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) today reported its financial and operating results for the second quarter ended June 30, 2019. All Amounts are in U.S. Dollars Highlights On June 6, 2019, the Company announc...
News, Short Squeeze, Breakout and More Instantly...
Aeterna Zentaris Inc. Company Name:
AEZS Stock Symbol:
NASDAQ Market:
Aeterna Zentaris Inc. Website:
2024-07-17 19:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
TORONTO, ONTARIO, July 16, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the "Company"), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products and active ingredients for he...
Aeterna Zentaris Inc. (NASDAQ: AEZS) is one of today's top gainers. The company's shares have moved 24.97% on the day to $6.7. Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimore...